These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers]. Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296 [TBL] [Abstract][Full Text] [Related]
6. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Chen PL; Roh W; Reuben A; Cooper ZA; Spencer CN; Prieto PA; Miller JP; Bassett RL; Gopalakrishnan V; Wani K; De Macedo MP; Austin-Breneman JL; Jiang H; Chang Q; Reddy SM; Chen WS; Tetzlaff MT; Broaddus RJ; Davies MA; Gershenwald JE; Haydu L; Lazar AJ; Patel SP; Hwu P; Hwu WJ; Diab A; Glitza IC; Woodman SE; Vence LM; Wistuba II; Amaria RN; Kwong LN; Prieto V; Davis RE; Ma W; Overwijk WW; Sharpe AH; Hu J; Futreal PA; Blando J; Sharma P; Allison JP; Chin L; Wargo JA Cancer Discov; 2016 Aug; 6(8):827-37. PubMed ID: 27301722 [TBL] [Abstract][Full Text] [Related]
7. Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy. Novotny JF; Cogswell J; Inzunza H; Harbison C; Horak C; Averbuch S Ann Oncol; 2016 Oct; 27(10):1966-9. PubMed ID: 27502705 [TBL] [Abstract][Full Text] [Related]
8. Current status of immunotherapy for non-small-cell lung cancer. Imbimbo M; Lo Russo G; Blackhall F Tumori; 2016 Aug; 102(4):337-51. PubMed ID: 27443896 [TBL] [Abstract][Full Text] [Related]
9. Biomarkers of response to PD-1/PD-L1 inhibition. Maleki Vareki S; Garrigós C; Duran I Crit Rev Oncol Hematol; 2017 Aug; 116():116-124. PubMed ID: 28693793 [TBL] [Abstract][Full Text] [Related]
11. Biomarkers of response to immune checkpoint blockade in cancer treatment. Fujii T; Naing A; Rolfo C; Hajjar J Crit Rev Oncol Hematol; 2018 Oct; 130():108-120. PubMed ID: 30196907 [TBL] [Abstract][Full Text] [Related]
12. Immune and molecular correlates in melanoma treated with immune checkpoint blockade. Byrne EH; Fisher DE Cancer; 2017 Jun; 123(S11):2143-2153. PubMed ID: 28543699 [TBL] [Abstract][Full Text] [Related]
13. Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application. Tray N; Weber JS; Adams S Cancer Immunol Res; 2018 Oct; 6(10):1122-1128. PubMed ID: 30279188 [TBL] [Abstract][Full Text] [Related]
14. Biomarkers for immune checkpoint inhibitors: The importance of tumor topography and the challenges to cytopathology. Clark DP Cancer Cytopathol; 2018 Jan; 126(1):11-19. PubMed ID: 29131530 [TBL] [Abstract][Full Text] [Related]
15. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers. Sweis RF; Galsky MD Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246 [TBL] [Abstract][Full Text] [Related]
16. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer. Hu ZI; Ho AY; McArthur HL Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141 [TBL] [Abstract][Full Text] [Related]
17. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment]. Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419 [TBL] [Abstract][Full Text] [Related]
18. De-novo and acquired resistance to immune checkpoint targeting. Syn NL; Teng MWL; Mok TSK; Soo RA Lancet Oncol; 2017 Dec; 18(12):e731-e741. PubMed ID: 29208439 [TBL] [Abstract][Full Text] [Related]
19. Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapy. Qin BD; Jiao XD; Zang YS Med Hypotheses; 2018 Jul; 116():111-113. PubMed ID: 29857892 [TBL] [Abstract][Full Text] [Related]